Xiangyang Wu

Prof. Dr. Xiangyang Wu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ZYzhang yinchang
zhang yinchang
YZYantao Zhang
Yantao Zhang
JZJinlong Zang
Jinlong Zang
YLYongnan Li
Yongnan Li
XWXiangyang Wu
Xiangyang Wu
Cardiovascular disease morbidity/mortality are increasing due to an aging population and the rising prevalence of diabetes and obesity. Therefore, innovative cardioprotective measures are required to reduce cardiovascular disease morbidity/mortality. The role of necroptosis in myocardial ischemia–reperfusion injury (MI–RI) is beyond doubt, but the molecular mechanisms of necroptosis remain incompletely elucidated. Growing evidence suggests that MI–RI frequently results from the superposition of multiple pathways, with autophagy, ferroptosis, and CypD-mediated mitochondrial damage, and necroptosis all contributing to MI–RI. Receptor-interacting protein kinases (RIPK1 and RIPK3) as well as mixed lineage kinase domain-like pseudokinase (MLKL) activation is accompanied by the activation of other signaling pathways, such as Ca2+/calmodulin-dependent protein kinase II (CaMKII), NF-κB, and JNK-Bnip3. These pathways participate in the pathological process of MI–RI. Recent studies have shown that inhibitors of necroptosis can reduce myocardial inflammation, infarct size, and restore cardiac function. In this review, we will summarize the molecular mechanisms of necroptosis, the links between necroptosis and other pathways, and current breakthroughs in pharmaceutical therapies for necroptosis.

17 April 2023 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
YMYong Mao
Yong Mao
CWCingting Wang
Cingting Wang
YLYongnan Li
Yongnan Li
XGXinqiang Guan
Xinqiang Guan
XZXiaopeng Zhang
Xiaopeng Zhang
XWXiangyang Wu
Xiangyang Wu
Objectives: Ruptured sinus of Valsalva aneurysm (RSVA) often has an abrupt onset, and can chest pain, acute heart failure, and even sudden death. The effectiveness of different treatment modalities remains controversial. Thus, we completed a meta-analysis to evaluate the efficiency and safety of traditional surgery vs. percutaneous closure (PC) for RSVA.Methods: We carried out a meta-analysis using PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), WanFang Data, and the China Science and Technology Journal Database. The primary outcome was comparing in-hospital mortality between the two procedures, and the secondary outcome was documenting postoperative residual shunts, postoperative aortic regurgitation, and length of hospital stay in the two groups. Differences were expressed as odds ratios (ORs) with 95% confidence intervals (CIs) to assess the relationships between predefined surgical variables and clinical outcomes. This meta-analysis was conducted using Review Manager software (version 5.3).Results: The final qualifying studies included 330 patients from 10 trials (123 in the percutaneous closure group, and 207 in the surgical repair group). When PC was compared to surgical repair, there were no statistically significant differences in in-hospital mortality (overall OR: 0.47, 95%CI 0.05–4.31, P = 0.50). However, percutaneous closure did significantly decrease the average length of hospital stay (OR: −2.13, 95% CI −3.05 to −1.20, P < 0.00001) when compared to surgical repair, but there were no significant between-group differences in the rates of postoperative residual shunts (overall OR: 1.54, 95%CI 0.55–4.34, P = 0.41) or postoperative aortic regurgitation (overall OR: 1.54, 95%CI 0.51–4.68, P = 0.45).Conclusion: PC may become a valuable alternative to surgical repair for RSVA.

25 June 2025 in General Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
HYHanyun Yi
Hanyun Yi
YLYongnan Li
Yongnan Li
QZQiming Zhao
Qiming Zhao
XWXiangyang Wu
Xiangyang Wu

4 December 2024 in BMJ Open Respiratory Research
Verified
Journal Article
Open access
PDF file
SWShi-Lin Wei
Shi-Lin Wei
JDJun-Zhe Du
Jun-Zhe Du
KZKe-Rong Zhai
Ke-Rong Zhai
JYJian-Bao Yang
Jian-Bao Yang
RZRan Zhang
Ran Zhang
BLBin Li
Bin Li
Background: In recent years, dexamethasone (Dex) has been used to treat acute respiratory distress syndrome (ARDS) in patients with COVID-19 and achieved promising outcomes. Venovenous extracorporeal membrane oxygenation (VV ECMO) support for patients with ARDS has increased significantly worldwide. However, it remains unknown whether Dex could improve the efficiency of VV ECMO to reduce lung injury. Here, we investigate the combined efficiency of VV ECMO and Dex in rats with acute lung injury (ALI). Methods: We established VV ECMO in oleic acid (OA)-treated ALI rats and administered Dex. We conducted HE staining and evaluated lung and bronchoalveolar lavage (BAL) fluid cytokines to assess lung injury and inflammation. Furthermore, we investigated the activation of Hippo/YAP signalling in alveolar epithelial type II cell (AT2)-mediated alveolar epithelial repair using quantitative PCR, Western blotting and immunofluorescence. In vitro, the human alveolar epithelial cell line A549 was used to investigate the key role of YAP in alveolar epithelial cell differentiation. Results: VV ECMO combined with Dex alleviated OA-induced lung injury and pulmonary inflammation. Pulmonary oedema and exudation were significantly alleviated, and the lung and BAL levels of IL-6, IL-8 and TNF-α were significantly reduced compared with those observed with ECMO alone. In addition, VV ECMO combined with Dex treatment protected alveolar epithelial cells by activating Hippo/YAP signalling. In vitro, Dex promoted YAP expression and alveolar epithelial cell differentiation, whereas YAP knockdown inhibited YAP-mediated differentiation. Conclusions: Our findings suggest that adjuvant Dex treatment during VV ECMO could alleviate ALI and pulmonary inflammation by activating the Hippo/YAP signalling pathway, which promoted alveolar regeneration and AT2 differentiation.

4 February 2026 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
XHXuchao Hu
Xuchao Hu
YZYinchang Zhang
Yinchang Zhang
QZQiming Zhao
Qiming Zhao
YLYongnan Li
Yongnan Li
XWXiangyang Wu
Xiangyang Wu
Cardiovascular diseases (CVDs), such as atherosclerosis, myocardial remodeling, myocardial ischemia-reperfusion (I/R) injury, heart failure, and oxidative stress, are among the greatest threats to human health globally. The molecular mechanisms underlying CVDs have not yet been fully elucidated, but progress has been made in research on epigenetics in CVDs. Post-translational modifications (PTMs), which involve the covalent attachment of functional groups to modulate protein structure and function, represent a critical regulatory mechanism. These modifications enhance the functional diversity of the proteome without the need for de novo protein synthesis. Traditional types of PTMs, such as phosphorylation, acetylation, and ubiquitination, are closely associated with the pathogenesis of CVDs. With the application of high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS), an increasing number of novel acylation modifications have been discovered, including propionylation, butylation, crotonylation, succinylation, lactylation, and isonicotinylation. A deeper understanding of the role of PTMs in CVDs is essential for unraveling their molecular regulatory mechanisms and identifying new biomarkers and therapeutic targets. This review summarizes the mechanisms related to the occurrence and development of CVDs associated with three novel acylation modifications: crotonylation, lactylation, and succinylation.

6 January 2023 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
YZYanchun Zhang
Yanchun Zhang
YLYongnan Li
Yongnan Li
YMYuMei Ma
YuMei Ma
YWYalin Wei
Yalin Wei
FHFengxiao He
Fengxiao He
XWXiangyang Wu
Xiangyang Wu
A 10-year-old girl presented with obvious cyanosis, and the saturation of arterial blood oxygen (SpO2) was decreased to 60.5% in the outpatient examination. Computed tomography angiography (CTA) and echocardiography suggested congenitally corrected transposition of the great arteries (ccTGAs), membranous ventricular septal aneurysm (MVSA), atrial septal defect (ASD), severe pulmonary stenosis (PS), and severe tricuspid regurgitation (TR). Due to the complex pathological anatomical structures, the three-dimensional printed model was used for preoperative assessment. After a comprehensive evaluation was completed, the operation was performed by physiological correction under cardiopulmonary bypass, including the resection of MVSA, repair using the bovine pericardial patch for ASD, and linear valvuloplasty of the tricuspid valve. Due to the special anatomical structures of ccTGA, PS was treated by extracardiac pipe technique. After the operation, the patient recovered well, cyanosis disappeared, SpO2 was up to 96%, and the extracardiac pipe was well-functioning without regurgitation or obstruction.